# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Isaac Newton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN011-SYN
- Date: 2026-10-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Okonkwo-Fairbanks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Three-week depression and mercury exposure review. **S**

## History of present illness

Mr. Newton returns three weeks after starting sertraline 50 mg and a month after removal from exposure. Mild nausea in the first few days settled; he has had no other side effects and has missed no doses. He has had three sessions of cognitive behavioral therapy. He sleeps about five and a half hours, keeps the sleep window, and no longer dozes in the evening. He eats three meals a day. He has written to apologize to the friends he accused and has had warm replies; he no longer believes anyone was plotting against him. He is teaching fully and has begun to answer letters again. He has had no thoughts of death or of harming himself or anyone else. The safety office has not yet re-measured the laboratory after its cleaning, so it remains closed. He brought his 24-hour urine collection this morning. **S**

| Element | Detail |
|---|---|
| Medication | Sertraline 50 mg for three weeks; no side effects now |
| Psychotherapy | Three CBT sessions |
| Sleep | About five and a half hours; no evening dozing |
| Suspicious ideas | Resolved; apologies made and accepted |
| Exposure | None for a month; laboratory still closed |
| PHQ-9 | 14, down from 20 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite better; weight 64.8 kg |
| Ears, nose, mouth, and throat | Negative | No gum or mouth symptoms |
| Neurological | Negative | No tremor, numbness, or headache |
| Psychiatric | Positive | Mood lifting but still low most mornings; no suicidal thoughts, elevated mood, or agitation |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 64.8 kg; BMI 22.4 kg/m². All vital signs are synthetic.

PHQ-9: 14; GAD-7: 7; Blood mercury: 3.1 ug/L; 24-hour urine mercury: 31 ug/L (high); Urine mercury per gram creatinine: 27 ug/g{creat} (high). All results are synthetic.

## Change since baseline

- PHQ-9: 20 at baseline, 14 at this visit **S**
- GAD-7: 11 at baseline, 7 at this visit **S**
- Blood mercury: 9.4 ug/L (high) at baseline, 3.1 ug/L at this visit **S**
- 24-hour urine mercury: 46 ug/L (high) at baseline, 31 ug/L (high) at this visit **S**
- Urine mercury per gram creatinine: 41 ug/g{creat} (high) at baseline, 27 ug/g{creat} (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Better color; tidier |
| Mouth | Gums healthy |
| Neurological | No tremor; spiral drawing normal |
| Mental status | Engaged, at times humorous; mood "lighter"; affect more reactive; no suspicious or fixed false beliefs; no suicidal or homicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, single episode, severe, without psychotic features** (F32.2). PHQ-9 14, 30 percent below baseline, and GAD-7 7, three weeks into sertraline and CBT: early improvement, not yet a response. Suspicious ideas have resolved. No side effects; no suicidal thoughts or thoughts of harming others. **S**
   - Continue sertraline 50 mg; review in three weeks.
   - If the PHQ-9 has not fallen by at least 50 percent after six to eight weeks, increase to 100 mg.
   - Continue weekly CBT and collaborative-care review.
   - Safety plan unchanged; 988 Suicide & Crisis Lifeline confirmed.
2. **Raised urine mercury from occupational exposure** (R82.6). Urine mercury 31 ug/L (27 ug/g creatinine), down from 46 ug/L a month after removal, as expected with a urinary half-life of one to two months; blood mercury 3.1 ug/L, now normal. No signs of toxicity. **S**
   - Repeat 24-hour urine mercury, creatinine, and urine albumin-to-creatinine ratio at three months.
   - No return to the laboratory until it is re-measured and the fume hood is fitted.
3. **Chronic insomnia comorbid with depression** (G47.00). About five and a half hours; sleep efficiency improved on the diary. **S**
   - Widen the sleep window by 15 minutes.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 14, down from 20 (30 percent); item 9 scored 0 |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 7, down from 11 |
| Survey | Suicide and violence risk reassessment (C-SSRS Since Last Visit, PHQ-9 item 9, and thoughts of harming others) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; no thoughts of harming others; PHQ-9 item 9 scored 0 |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Completed today | Done at the preventive visit two weeks after the start (no side effects) and again today |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; early nausea resolved; no bleeding, restlessness, or sexual side effects |
| Laboratory | 24-hour urine mercury with creatinine correction, and blood mercury | At the exposure assessment, then 4 to 6 weeks after removal and at 3 months | Completed today | Urine 31 ug/L and 27 ug/g creatinine, falling; blood 3.1 ug/L, normal; next at three months |
| Laboratory | Kidney function and urine protein | At the exposure assessment and at 3 months | Due | Normal at intake; due at three months |
| Examination | Signs of mercury toxicity: tremor (postural and intention), handwriting, gums and mouth, erethism, peripheral neuropathy | At the exposure assessment and at each follow-up while levels are raised | Completed today | No tremor, gingivitis, or neuropathy |
| Self-management | Workplace hazard control: re-measurement of mercury vapor after decontamination | After decontamination and before any return to the laboratory | Deferred | Missed: the safety office planned to re-measure the laboratory within two weeks of cleaning, but has not yet done so. No harm: the laboratory has stayed closed, he has had no exposure, and his urine mercury is falling. Corrective action: the clinic wrote to the safety office asking for the measurement and the fume-hood installation date, and his return to laboratory work stays on hold until both are confirmed |
| Medication safety | Chelation and provoked (chelator-challenge) urine testing | Only for symptomatic patients with high levels, decided with a medical toxicologist | Not indicated | Urine mercury below 100 ug/L with no tremor, gingivitis, or kidney injury; removal from exposure comes first, and provoked testing is not valid |
| Examination | Weight and nutrition | Every visit while weight is below his usual | Completed today | 64.8 kg, up 1.0 kg since the diagnosis visit; three meals a day |
| Self-management | Psychotherapy, sleep, and activity | Every visit during active treatment | Completed today | Three CBT sessions; sleep window widened; teaching fully; walks most days |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only; no antipsychotic, because there are no psychotic features |

## Goal progress

- Toxic and other medical causes assessed by the second visit. Outcome by 2026-10-08: Blood count, metabolic panel, TSH, vitamin B12, kidney tests, blood lead, and MoCA normal; blood and urine mercury raised from his work, below levels linked to overt toxicity. **S**
- No further exposure to mercury and other metals until the laboratory is made safe. In progress; target 2027-01-31. **S**
- Response (PHQ-9 down by at least 50 percent) by eight to twelve weeks of treatment, then remission (PHQ-9 below 5). In progress; target 2026-12-31. **S**
- No suicidal thoughts and no thoughts of harming others. In progress; target 2026-12-31. **S**
- At least six hours of sleep most nights without hypnotics. In progress; target 2026-12-31. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- Evaluating Mercury Exposure: Information for Health Care Providers (2018), Agency for Toxic Substances and Disease Registry
- NIOSH Pocket Guide to Chemical Hazards: Mercury compounds [except (organo) alkyls] (as Hg) (2026), National Institute for Occupational Safety and Health
- American College of Medical Toxicology Position Statement on Post-Chelator Challenge Urinary Metal Testing (2010), American College of Medical Toxicology (Journal of Medical Toxicology)
- Use and Misuse of Metal Chelation Therapy (McKay CA, editorial) and Recommendations for Provoked Challenge Urine Testing (Ruha AM), proceedings of the ACMT symposium (2013), American College of Medical Toxicology (Journal of Medical Toxicology)

## Follow-up

- Depression review in three weeks; urine mercury and kidney tests at three months; second zoster dose in two to six months. **S**

